Optimal pharmacological treatment and adherence to medication in secondary prevention of cardiovascular events in Spain: Results from the CAPS study

Cardiovascular Therapeutics

Volumn 35, Issue 2, 2017, Pages

  Cordero, Alberto ^a   Rodriguez Padial, Luis ^b   Batalla, Alberto ^c   López Barreiro, Luis ^d   Torres Calvo, Francisco ^d   Castellano, Jose M ^d   Ruiz, Emilio ^e   Bertomeu Martínez, Vicente ^a  

^a HOSPITAL UNIVERSITARIO DE SAN JUAN   (Spain)

^b Hospital Univ de Toledo   (Spain)

^c Department of Cardiology   (Spain)

^d CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

^e Sant Joan Despi   (Spain)

Author keywords

Adherence; Cardiovascular; Optimal treatment; Secondary prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; CARDIOVASCULAR AGENT;

AGED; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; EDUCATIONAL STATUS; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MORISKY GREEN QUESTIONNAIRE; MULTICENTER STUDY; OBSERVATIONAL STUDY; OPTIMAL MEDICAL TREATMENT; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRESCRIPTION; QUESTIONNAIRE; SECONDARY PREVENTION; SPAIN; CARDIOVASCULAR DISEASES; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION DRUG THERAPY; MIDDLE AGED; POLYPHARMACY; PRACTICE GUIDELINE; PROCEDURES; PROTOCOL COMPLIANCE; RECURRENT DISEASE; RISK FACTOR; SOCIOECONOMICS; STANDARDS; TIME FACTOR; TREATMENT OUTCOME; TRENDS;

AGED; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; DRUG PRESCRIPTIONS; DRUG THERAPY, COMBINATION; FEMALE; GUIDELINE ADHERENCE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; POLYPHARMACY; PRACTICE GUIDELINES AS TOPIC; PRACTICE PATTERNS, PHYSICIANS'; RECURRENCE; RISK FACTORS; SECONDARY PREVENTION; SOCIOECONOMIC FACTORS; SPAIN; SURVEYS AND QUESTIONNAIRES; TIME FACTORS; TREATMENT OUTCOME;

EID: 85014912209     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/1755-5922.12240     Document Type: Article

References (34)

1. Naghavi M, Wang H, Lozano R, et al. Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;385:117–171.
2. WHO. 2015. Cardiovascular diseases (CVDs) (World Health Organization).
3. Nichols M, Townsend N, Scarborough P, Rayner M. Cardiovascular disease in Europe 2014: epidemiological update. Eur Heart J. 2014;35:2950–2959.
4. Baena-Díez JM, Vidal-Solsona M, Byram AO, González-Casafont I, Ledesma-Ulloa G, Martí-Sans N. Epidemiología de las enfermedades cardiovasculares en atención primaria. Estudio Cohorte Zona Franca de Barcelona. Rev Española Cardiol. 2010;63:1261–1269.
5. Peeters A, Mamun AA, Willekens F, Bonneux L. A cardiovascular life history. A life course analysis of the original Framingham Heart Study cohort. Eur Heart J. 2002;23:458–466.
6. Arós F, Heras M, Vila J, et al. Reduction in 28 days and 6 months of acute myocardial infarction mortality from 1995 to 2005. Data from PRIAMHO I, II and MASCARA registries. Rev Española Cardiol. 2011;64:972–980.
7. National Center for Health Statistics. 2015. Deaths: Final Data for 2013.
8. Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34:2949–3003.
9. Perk J, De Backer G, Gohlke H, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur Heart J. 2012;33:1635–1701.
10. Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2011;32:2999–3054.
11. Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33:2569–2619.
12. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003;326:1419.
13. Lim SS, Gaziano TA, Gakidou E, et al. Prevention of cardiovascular disease in high risk individuals in low- income and middle income countries: health effects and costs. Lancet. 2007;6736:1–9.
14. Bertomeu V, Cordero A, Quiles J, Mazón P, Aznar J, Bueno H. Control de los factores de riesgo y tratamiento de los pacientes con cardiopatía isquémica: registro TRECE. Rev Española Cardiol. 2009;62:807–811.
15. Zeymer U, Berkenboom G, Coufal Z, et al. Predictors, cost, and outcomes of patients with acute coronary syndrome who receive optimal secondary prevention therapy: results from the antiplatelet treatment observational registries (APTOR). Int J Cardiol. 2013;170:239–245.
16. Ferreira-González I, Carrillo X, Martín V, et al. Interhospital variability in drug prescription after acute coronary syndrome: insights from the ACDC study. Rev Esp Cardiol (Engl Ed). 2015;69:117–124doi/10.1016/j.rec.2015.04.018.
17. Castellano JM, Sanz G, Peñalvo JL, et al. A polypill strategy to improve adherence: results from the FOCUS project. J Am Coll Cardiol. 2014;64:2071–2082.
18. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487–497.
19. WHO. 2003. Adherence to long-term therapies: evidence for action (World Health Organization).
20. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009;119:3028–3035.
21. Bosworth HB, Granger BB, Mendys P, et al. Medication adherence: a call for action. Am Heart J. 2011;162:412–424.
22. Cutler DM, Everett W. Thinking outside the pillbox — medication adherence as a priority for health care reform. N Engl J Med. 2010;362:1553–1555.
23. Chowdhury R, Khan H, Heydon E, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J. 2013;34:2940–2948.
24. Zhao D, Liu J, Xie W, Qi Y. Cardiovascular risk assessment: a global perspective. Nat Rev Cardiol. 2015;12:301–311.
25. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24:67–74.
26. Val Jiménez A, Amorós Ballestero G, Martínez Visa P, Fernández Ferré ML, León Sanromà M. Descriptive study of patient compliance in pharmacologic antihypertensive treatment and validation of the Morisky and Green test. Aten Primaria. 1992;10:767–770.
27. Ferrán M, Parcet J, Cassabella B, Fernández M, De la Torre M. Educación sanitaria a pacientes hipertensos: propuesta de un test de conocimientos y cumplimiento. Aten primaria/Soc Esp Med Fam y Comunitaria Primaria. 1998;5:35–38.
28. Sedlis SP, Hartigan PM, Teo KK, et al. Effect of PCI on long-term survival in patients with stable ischemic heart disease. N Engl J Med. 2015;373:1937–1946.
29. Kotseva K, Wood D, De Bacquer D, et al. EUROASPIRE IV: a European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol. 2015;23:636–648.
30. Sanfélix-Gimeno G, Peiró S, Ferreros I, et al. Adherence to evidence-based therapies after acute coronary syndrome: a retrospective population-based cohort study linking hospital, outpatient, and pharmacy health information systems in Valencia, Spain. J Manag Care Pharm. 2013;19:247–257.
31. Patel A, Cass A, Peiris D, et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. Eur J Prev Cardiol. 2015;22:920–930.
32. Selak V, Elley CR, Bullen C, et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ. 2014;348(May):g3318.
33. Becerra V, Gracia A, Desai K, et al. Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK. BMJ Open. 2015;5(2044-6055 (Electronic)):e007111.
34. Yusuf S, Amir A, Jackie B, et al. Combination pharmacotherapy to prevent cardiovascular disease: present status and challenges. Eur Heart J. 2014;35:353–364.